Biophytis (EPA:ALBPS) | WebDisclosure

BRIEF

published on 03/22/2024 at 07:05, 8 months 1 day ago

Biophytis dévoile son étude de phase 3 sur le traitement de la sarcopénie

Biophytis Sarcopénie Ruvembri Étude De Phase 3 ICFSR
BRIEF

published on 03/22/2024 at 07:05, 8 months 1 day ago

Biophytis Unveils Phase 3 Sarcopenia Treatment Protocol

Biophytis Clinical Research RuvembriTM Sarcopenia Phase 3 Study
PRESS RELEASE

published on 03/22/2024 at 07:01, 8 months 1 day ago

Biophytis a présenté son protocole de phase 3 dans le traitement de la sarcopénie
Biophytis a présenté son protocole de phase 3 dans le traitement de la sarcopénie lors de l’ICFSR. L'étude SARA-31 vise à évaluer l'efficacité de RuvembriTM. La société recherche des partenaires pharmaceutiques pour le développer

Biophytis RuvembriTM Sarcopénie ICFSR Protocole De Phase 3
PRESS RELEASE

published on 03/22/2024 at 07:01, 8 months 1 day ago

Biophytis presented its phase 3 protocol in the treatment of sarcopenia
Biophytis presented its phase 3 protocol for treating sarcopenia with Ruvembri at ICFSR conference, showing promising results in phase 2 study

Biophytis Ruvembri Phase 3 Protocol Sarcopenia Treatment ICFSR Conference
REGULATED PRESS RELEASE

published on 03/22/2024 at 07:00, 8 months 1 day ago

Biophytis a présenté son protocole de phase 3 dans le traitement de la sarcopénie
Biophy's présente son protocole de phase 3 pour traiter la sarcopénie lors de l'ICFSR. L'étude SARA-31 évaluera l'efficacité de RuvembriTM. Biophytis recherche des partenaires pour le développement

Biophytis RuvembriTM Sarcopénie Biophy's Protocole De Phase 3
REGULATED PRESS RELEASE

published on 03/22/2024 at 07:00, 8 months 1 day ago

Biophytis presented its phase 3 protocol in the treatment of sarcopenia
Biophytis presents phase 3 protocol for sarcopenia treatment at ICFSR conference, showcasing the potential of RuvembriTM. CEO Stanislas Veillet seeks partners for drug development and financing

Biophytis RuvembriTM Clinical-stage Biotechnology Phase 3 Protocol Sarcopenia Treatment
BRIEF

published on 03/18/2024 at 07:05, 8 months 5 days ago

Biophytis annonce sa prochaine Assemblée Générale Mixte pour le 02 avril 2024

Biophytis Assemblée Générale Mixte Société Biotechnologique Vote Des Actionnaires Médicaments Vieillissement
BRIEF

published on 03/18/2024 at 07:05, 8 months 5 days ago

Biophytis Announces Combined General Meeting for April 2024

Biophytis RuvembriTM Clinical-stage Biotechnology Combined General Meeting Age-related Diseases
REGULATED PRESS RELEASE

published on 03/18/2024 at 07:00, 8 months 5 days ago

Assemblée générale mixte du 02 avril 2024
Assemblée générale mixte de Biophytis SA prévue le 02 avril 2024 à Paris. Actionnaires invités à voter en amont. Informations sur le site internet de la Société

Assemblée Générale Mixte Biophytis SA Vote Actionnaires Développement Médicaments Maladies Liées Au Vieillissement
REGULATED PRESS RELEASE

published on 03/18/2024 at 07:00, 8 months 5 days ago

Combined General Meeting of April 2, 2024
Biophytis SA will hold its Combined General Meeting (CGM) on April 2, 2024 at Sorbonne Université, Paris. Shareholders can vote in advance. The company specializes in developing therapies for age-related diseases

Therapeutics Combined General Meeting Biophytis SA Age-related Diseases CGM

Published on 11/22/2024 at 23:55, 23 hours 33 minutes ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 23 hours 58 minutes ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 1 day ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 1 day ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 1 day ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 1 day 5 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 1 day 5 hours ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 1 day 5 hours ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 1 day 6 hours ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 1 day 7 hours ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 17:45, 1 day 5 hours ago

IMMERSION : RFA 2023/2024
Published on 11/22/2024 at 16:15, 1 day 7 hours ago

NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Published on 11/22/2024 at 14:35, 1 day 8 hours ago

Communiqué de presse Thales
Published on 11/22/2024 at 14:35, 1 day 8 hours ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 16 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio

View all LES ECHOS COMFI WIRE

News